119 related articles for article (PubMed ID: 1991694)
1. Interleukin-1 modification of the effects of cyclophosphamide and fractionated irradiation.
Dorie MJ; Kallman RF; Cebulska-Wasilewska A
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):311-4. PubMed ID: 1991694
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 modulatory effect on the action of chemotherapeutic drugs and localized irradiation of the lip, duodenum, and tumor.
Zaghloul MS; Dorie MJ; Kallman RF
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):417-25. PubMed ID: 8514539
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide.
Milas L; Nakayama T; Hunter N; Jones S; Lin TM; Yamada S; Thames H; Peters L
Radiother Oncol; 1994 Mar; 30(3):247-53. PubMed ID: 8209009
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems.
Kallman RF; Rapacchietta D; Zaghloul MS
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):227-32. PubMed ID: 1991683
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 1 increases thymidine labeling index of normal tissues of mice but not the tumor.
Zaghloul MS; Dorie MJ; Kallman RF
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):805-11. PubMed ID: 8040027
[TBL] [Abstract][Full Text] [Related]
7. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
Law MP; Hirst DG; Brown JM
Br J Cancer; 1981 Aug; 44(2):208-18. PubMed ID: 7272187
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors.
Braunschweiger PG; Johnson CS; Kumar N; Ord V; Furmanski P
Cancer Res; 1988 Nov; 48(21):6011-6. PubMed ID: 3262418
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth and tumor radiosensitivity in mice given myeloprotective doses of fibroblast growth factors.
Ding I; Huang K; Snyder ML; Cook J; Zhang L; Wersto N; Okunieff P
J Natl Cancer Inst; 1996 Oct; 88(19):1399-404. PubMed ID: 8827018
[TBL] [Abstract][Full Text] [Related]
10. [Tumor immunity induced by local radiotherapy].
Yamashita T; Hayakawa Y; Hanajima K; Mochizuki S
Gan No Rinsho; 1983 Oct; 29(13):1506-11. PubMed ID: 6422094
[TBL] [Abstract][Full Text] [Related]
11. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
Twentyman PR
Br J Cancer; 1981 Jun; 43(6):745-55. PubMed ID: 6264941
[TBL] [Abstract][Full Text] [Related]
12. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
13. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
14. Leech salivary gland extract from Haementeria officinalis, a potent inhibitor of cyclophosphamide- and radiation-induced artificial metastasis enhancement.
Gasic GJ; Iwakawa A; Gasic TB; Viner ED; Milas L
Cancer Res; 1984 Dec; 44(12 Pt 1):5670-6. PubMed ID: 6498828
[TBL] [Abstract][Full Text] [Related]
15. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
Krupke DM; Fuller J; Aslakson C; Evans R
Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
[TBL] [Abstract][Full Text] [Related]
16. The effect of treatment in fractionated schedules with the combination of X-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin.
Lelieveld P; Scoles MA; Brown JM; Kallman RF
Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):111-21. PubMed ID: 4038500
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors.
Nishiguchi I; Willingham V; Milas L
Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):555-8. PubMed ID: 2318687
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam M; Ottenjann S; Künzel G; Busch R; Erhardt W; Nieder C; Molls M
Strahlenther Onkol; 2006 Apr; 182(4):231-9. PubMed ID: 16622625
[TBL] [Abstract][Full Text] [Related]
19. Combinations of CCNU, MISO, and fractionated radiotherapy.
Siemann DW; Alliet KL
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1379-82. PubMed ID: 3759559
[TBL] [Abstract][Full Text] [Related]
20. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population.
Karnbach C; Daws MR; Niemi EC; Nakamura MC
J Immunol; 2001 Sep; 167(5):2569-76. PubMed ID: 11509597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
